SEHK:2616Biotechs
CStone Pharmaceuticals (SEHK:2616) Valuation Spotlight After Key Pipeline Advances and IND Milestone
CStone Pharmaceuticals (SEHK:2616) is in focus after two important pipeline updates landed this week. The company will showcase preclinical data for its CS2015 antibody at ACAAI 2025. In addition, CS2009 has cleared an IND milestone in China.
See our latest analysis for CStone Pharmaceuticals.
CStone’s share price has surged 148% year-to-date and delivered an exceptional 227% total shareholder return over the past year. This performance has been fueled in recent days by promising advances in...